{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T17:05:51Z","timestamp":1779728751345,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2022-A-23"],"award-info":[{"award-number":["2022-A-23"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10147-026-03025-y","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:54:01Z","timestamp":1775559241000},"page":"1053-1062","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends and current status in anticancer therapy for older patients with non-small cell lung cancer in Japan, 2016\u20132021"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-2003","authenticated-orcid":false,"given":"Tamaki","family":"Kakuwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-0898","authenticated-orcid":false,"given":"Go","family":"Naka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8337-5005","authenticated-orcid":false,"given":"Tomone","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7601-4295","authenticated-orcid":false,"given":"Taisuke","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-785X","authenticated-orcid":false,"given":"Yuichi","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9933-2106","authenticated-orcid":false,"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"3025_CR1","unstructured":"World cancer research fund, Worldwide cancer data. https:\/\/www.wcrf.org\/cancer-trends\/worldwide-cancer-data\/ (2022). Accessed 11 Oct 2024"},{"key":"3025_CR2","unstructured":"Cancer and disease control division, Ministry of health, labour and welfare. Cancer incidence of Japan 2020. https:\/\/www.mhlw.go.jp\/content\/10900000\/001231386.pdf (2020). Accessed 11 Oct 2024"},{"key":"3025_CR3","unstructured":"The Japan Lung Cancer Society (2021) Guidelines for Diagnosis and Treatment of Lung Cancer\/Malignant Pleural Mesothelioma\/Thymic tumor, 2021. Kanehara Shuppan. Tokyo"},{"key":"3025_CR4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J et al (2020) Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 383:1711\u20131723. https:\/\/doi.org\/10.1056\/NEJMoa2027071","journal-title":"N Engl J Med"},{"key":"3025_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T et al (2023) Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 389:491\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa2302983","journal-title":"N Engl J Med"},{"key":"3025_CR6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S et al (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386:1973\u20131985. https:\/\/doi.org\/10.1056\/NEJMoa2202170","journal-title":"N Engl J Med"},{"key":"3025_CR7","doi-asserted-by":"publisher","unstructured":"Maemondo M, Minegishi Y, Inoue A et al (2012) First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 7:1417\u20131422. https:\/\/doi.org\/10.1097\/JTO.0b013e318260de8b. Erratum in: (2012) J. Thorac. Oncol., Gemmah, Akihiko [corrected to Gemma, Akihiko]. 7:e33","DOI":"10.1097\/JTO.0b013e318260de8b"},{"key":"3025_CR8","doi-asserted-by":"publisher","first-page":"23140","DOI":"10.1038\/s4159802102561z","volume":"11","author":"G Yamamoto","year":"2021","unstructured":"Yamamoto G, Asahina H, Honjo O et al (2021) First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). Sci Rep 11:23140. https:\/\/doi.org\/10.1038\/s4159802102561z","journal-title":"Sci Rep"},{"key":"3025_CR9","doi-asserted-by":"publisher","first-page":"e196828","DOI":"10.1001\/jamaoncol.2019.6828","volume":"6","author":"I Okamoto","year":"2020","unstructured":"Okamoto I, Nokihara H, Nomura S et al (2020) Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced non-squamous non-small cell lung cancer: a Phase 3 randomized clinical trial. JAMA Oncol 6:e196828. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6828","journal-title":"JAMA Oncol"},{"key":"3025_CR10","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/S2666-7568(21)00255-5","volume":"2","author":"Y Kogure","year":"2021","unstructured":"Kogure Y, Iwasawa S, Saka H et al (2021) Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (Capital): a randomized, multicenter, open-label, phase 3 trial. Lancet Healthy Longev 2:e791\u2013e800. https:\/\/doi.org\/10.1016\/S2666-7568(21)00255-5","journal-title":"Lancet Healthy Longev"},{"key":"3025_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/jjco\/hyy032","volume":"48","author":"A Okuyama","year":"2018","unstructured":"Okuyama A, Higashi T (2018) Patterns of cancer treatment in different age groups in Japan: an analysis of hospital-based cancer registry data, 2012\u20132015. Jpn J Clin Oncol 48:417\u2013425. https:\/\/doi.org\/10.1093\/jjco\/hyy032","journal-title":"Jpn J Clin Oncol"},{"key":"3025_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/0284186X.2021.2000637","volume":"61","author":"L Will\u00e9n","year":"2022","unstructured":"Will\u00e9n L, Berglund A, Bergstr\u00f6m S et al (2022) Are older patients with non-small cell lung cancer receiving optimal care? A population-based study. Acta Oncol 61:309\u2013317. https:\/\/doi.org\/10.1080\/0284186X.2021.2000637","journal-title":"Acta Oncol"},{"key":"3025_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.lungcan.2017.04.005","volume":"108","author":"EJ Driessen","year":"2017","unstructured":"Driessen EJ, Aarts MJ, Bootsma GP et al (2017) Trends in treatment and relative survival among non-small Cell Lung Cancer patients in the Netherlands (1990\u20132014): disparities between younger and older patients. Lung Cancer 108:198\u2013204. https:\/\/doi.org\/10.1016\/j.lungcan.2017.04.005","journal-title":"Lung Cancer"},{"key":"3025_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.6004\/jnccn.2021.0043","volume":"19","author":"E Dotan","year":"2021","unstructured":"Dotan E, Walter LC, Browner IS et al (2021) NCCN Guidelines\u00ae Insights: Older Adult Oncology, version 1.2021. J Natl Compr Canc Netw 19:1006\u20131019. https:\/\/doi.org\/10.6004\/jnccn.2021.0043","journal-title":"J Natl Compr Canc Netw"},{"key":"3025_CR15","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/jjco\/hyab036","volume":"51","author":"A Okuyama","year":"2021","unstructured":"Okuyama A, Tsukada Y, Higashi T (2021) Coverage of the hospital-based cancer registries and the designated cancer care hospitals in Japan. Jpn J Clin Oncol 51:992\u2013998. https:\/\/doi.org\/10.1093\/jjco\/hyab036","journal-title":"Jpn J Clin Oncol"},{"key":"3025_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ejcts\/ezx215","volume":"53","author":"CC Yang","year":"2018","unstructured":"Yang CC, Fong Y, Lin LC et al (2018) The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. Eur J Cardiothorac Surg 53:235\u2013240. https:\/\/doi.org\/10.1093\/ejcts\/ezx215","journal-title":"Eur J Cardiothorac Surg"},{"key":"3025_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","volume":"13","author":"S Atagi","year":"2012","unstructured":"Atagi S, Kawahara M, Yokoyama A et al (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13:671\u2013678. https:\/\/doi.org\/10.1016\/S1470-2045(12)70139-0","journal-title":"Lancet Oncol"},{"key":"3025_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3892\/mco.2014.249","volume":"2","author":"J Takeshita","year":"2014","unstructured":"Takeshita J, Masago K, Fujita S et al (2014) Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: a case series of 20 patients. Mol Clin Oncol 2:454\u2013460. https:\/\/doi.org\/10.3892\/mco.2014.249","journal-title":"Mol Clin Oncol"},{"key":"3025_CR19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"3025_CR20","doi-asserted-by":"publisher","first-page":"100251","DOI":"10.1016\/j.jtocrr.2021.100251","volume":"2","author":"SCM Lau","year":"2021","unstructured":"Lau SCM, Ryan M, Weiss J et al (2021) Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage III NSCLC: safety and efficacy. JTO Clin Res Rep 2:100251. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100251","journal-title":"JTO Clin Res Rep"},{"key":"3025_CR21","doi-asserted-by":"publisher","first-page":"e26425","DOI":"10.2196\/26425","volume":"7","author":"M George","year":"2021","unstructured":"George M, Smith A, Sabesan S et al (2021) Physical comorbidities and their relationship with cancer treatment and its outcomes in older adult populations: systematic review. JMIR Cancer 7:e26425. https:\/\/doi.org\/10.2196\/26425","journal-title":"JMIR Cancer"},{"key":"3025_CR22","doi-asserted-by":"publisher","first-page":"175883592092343","DOI":"10.1177\/1758835920923430","volume":"12","author":"Z Duan","year":"2020","unstructured":"Duan Z, Cai G, Li J et al (2020) Cisplatin-induced renal toxicity in elderly people. Ther Adv Med Oncol 12:1758835920923430. https:\/\/doi.org\/10.1177\/1758835920923430","journal-title":"Ther Adv Med Oncol"},{"key":"3025_CR23","doi-asserted-by":"publisher","first-page":"11525","DOI":"10.1002\/cam4.5889","volume":"12","author":"D Morinaga","year":"2023","unstructured":"Morinaga D, Asahina H, Ito S et al (2023) Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. Cancer Med 12:11525\u201311541. https:\/\/doi.org\/10.1002\/cam4.5889","journal-title":"Cancer Med"},{"key":"3025_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"3025_CR25","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288\u20132301. https:\/\/doi.org\/10.1056\/NEJMoa1716948","journal-title":"N Engl J Med"},{"key":"3025_CR26","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"3025_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"3025_CR28","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381:2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"3025_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","volume":"10","author":"Y Tsukita","year":"2024","unstructured":"Tsukita Y, Tozuka T, Kushiro K et al (2024) Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer. JAMA Oncol 10:439\u2013447. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6277","journal-title":"JAMA Oncol"},{"key":"3025_CR30","unstructured":"Sabate E (2003) Adherence to long-term therapies: evidence for action. World Health Organization. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42682\/9241545992.pdf;jsessionid=5533CE0804BE2E0722B919623C4C2E05?sequence=1.Assessed28.11.2018. Accessed 3 Febr 2025"},{"key":"3025_CR31","unstructured":"Health Statistics Office, Director-General for Statistics, Information System Management and Industrial Relations, Ministry of health, labour and welfare, Survey of Medical Institutions (2021) https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/iryosd\/21\/dl\/02sisetu03.pdf. Accessed 29 Oct 2024"},{"key":"3025_CR32","unstructured":"Specific Diseases Control Division, Health Service Bureau, Ministry of health, labour and welfare. 19th Meeting of the Review Committee on Designation of Cancer Care Core Hospitals (Designation Results) (2021) https:\/\/www.mhlw.go.jp\/stf\/newpage_20158.html. Accessed 8 May 2025"},{"key":"3025_CR33","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1200\/JCO.2015.61.1558","volume":"33","author":"CC Lin","year":"2015","unstructured":"Lin CC, Bruinooge SS, Kirkwood MK et al (2015) Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. J Clin Oncol 33:3177\u20133185. https:\/\/doi.org\/10.1200\/JCO.2015.61.1558","journal-title":"J Clin Oncol"},{"key":"3025_CR34","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.19.00175","volume":"37","author":"GB Rocque","year":"2019","unstructured":"Rocque GB, Williams CP, Miller HD et al (2019) Impact of travel time on health care costs and resource use by phase of care for older patients with cancer. J Clin Oncol 37:1935\u20131945. https:\/\/doi.org\/10.1200\/JCO.19.00175","journal-title":"J Clin Oncol"},{"key":"3025_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12904-022-01017-z","volume":"21","author":"V Dos Santos Barros","year":"2022","unstructured":"Dos Santos Barros V, Bassi-Dibai D, Guedes CLR et al (2022) Barthel Index is a valid and reliable tool to measure the functional independence of cancer patients in palliative care. BMC Palliat Care 21:124. https:\/\/doi.org\/10.1186\/s12904-022-01017-z","journal-title":"BMC Palliat Care"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03025-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03025-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:53:06Z","timestamp":1779727986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03025-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3025"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03025-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7927085\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Go Naka reports a relationship with AstraZeneca that includes speaking and lecture fees. Takahiro Higashi is a member of the Journal of Gynecologic Oncology editorial board. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}